Home›Clinical trials›Kansas

GLP-1 clinical trials in Kansas: 12 recruiting now

By John Samaras, EditorRegistry checked September 4, 2026

12 GLP-1 clinical trials are recruiting at 16 sites in 7 cities across Kansas. Every site below is listed with its city and, where the sponsor publishes one, the number to call.

Every study recruiting in Kansas

  1. PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

    Phase 4. Run by Brigham and Women's Hospital. Registry number NCT05390892.

    A study testing whether a GLP-1 medicine, semaglutide, can help people lower blood sugar.

    Who can join. Adults 40 to 80, have type 2 diabetes.

    1 site in Kansas

  2. A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

    Phase 3. Run by Eli Lilly and Company. Registry number NCT07165028.

    A study testing whether a GLP-1, GIP and glucagon medicine from Lilly, retatrutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (MASLD), BMI 25+.

    3 sites in Kansas

  3. LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced

    Phase 3. Run by Boehringer Ingelheim. Registry number NCT06632444.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH) with liver scarring (fibrosis).

    2 sites in Kansas

  4. A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity

    Phase 3. Run by Novo Nordisk A/S. Registry number NCT07564414.

    A study testing whether a study medicine from Novo Nordisk, cagrisema, can help people with type 2 diabetes lose weight.

    Who can join. Adults 18+, have obesity, BMI 35+.

    2 sites in Kansas

    • Alliance for Multispecialty Research, Newton
    • Cotton O'Neil Diab & Endo Ctr, Topeka

  5. A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

    Phase 3. Run by Eli Lilly and Company. Registry number NCT07153471.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people ease joint pain.

    Who can join. Adults 18+, have osteoarthritis (joint pain), BMI 27+.

    1 site in Kansas

  6. A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

    Phase 3. Run by Novo Nordisk A/S. Registry number NCT07253285.

    A study testing whether a study medicine from Novo Nordisk, cagrilintide, can help people lose weight.

    Who can join. Children and teens 8 to 18, are overweight.

    1 site in Kansas

    • Cotton O'Neil Clinical Research Center, Topeka

  7. Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living

    Phase 3. Run by Kailera. Registry number NCT07284979.

    A study testing whether an investigational medicine from Kailera, KAI-9531, can help people lose weight.

    Who can join. Adults 18+, have obesity, BMI 35+.

    1 site in Kansas

    • Kailera Clinical Site, Newton

  8. A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron

    Phase 3. Run by AstraZeneca. Registry number NCT07662213.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    1 site in Kansas

    • Research Site, Wichita

  9. A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

    Phase 3. Run by Boehringer Ingelheim. Registry number NCT07754461.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    1 site in Kansas

  10. A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity

    Phase 2. Run by Eli Lilly and Company. Registry number NCT06143956.

    A study testing whether an investigational medicine from Lilly, LY3305677, can help people lose weight.

    Who can join. Adults 18 to 75, have obesity, BMI 27+.

    1 site in Kansas

    • Cotton O'Neil Diabetes & Endocrinology, Topeka. 785-354-9591

  11. A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

    Phase 2. Run by Novo Nordisk A/S. Registry number NCT07668388.

    A study testing whether an investigational medicine from Novo Nordisk, UBT251, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 75, have type 2 diabetes.

    1 site in Kansas

    • Cotton O'Neil Diabetes & Endocrinology, Topeka

  12. Gestational Response, Outcomes, and Weight After GLP-1 Use

    Run by University of Kansas Medical Center. Registry number NCT07743567.

    A study listed on ClinicalTrials.gov.

    Who can join. Adults 18 to 45, women only, have obesity or are overweight.

    1 site in Kansas

    • University of Kansas Medical Center, Kansas City. 913-588-5478

Source: ClinicalTrials.gov, the federal registry, read September 4, 2026. Open a study's registry record before you call: it can close to new participants at any time. GLP Chart does not enroll anyone, is not paid for clinical-trial referrals and has no relationship with any sponsor or site on this page.

Screening for a study can take weeks. If you need the drug now, Strut Health is the cheapest cash route on the chart, from $149 a month. That price buys compounded semaglutide, a pharmacy-made version that is not FDA-approved and is not Wegovy, Ozempic, Zepbound or Mounjaro.

Visit Strut Health ↗

Clinical trials by state

Every state with a GLP-1 study recruiting today. 48 of them.

John Samaras, editor of GLP Chart
John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this siteLinkedInContact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.